FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PFIZER INC			2. Date of Ev Requiring Sta (Month/Day/\)	atement /ear)	3. Issuer Name and Ticker or Trading Symbol Celladon Corp [CLDN]						
(Last) 235 E. 42ND	(First) (Middle)		01/23/2014		Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner				5. If Amendment, Date of Original Filed (Month/Day/Year)		
233 E. 42ND STREET					Officer (give title below)	Other (sp		6. Individual or Joint/Group Filing (Check Applicable Line)			
(Street)					Bolowy	DCIOW)		X	Form filed by	One Reporting Person	
NEW YORK	NY	10017							Form filed by Reporting Pe	More than One rson	
(City)	(State)	(Zip)									
Table I - Non-Derivative Securities Beneficially Owned											
				2. Amount of Securities Beneficially Owned (Instr. 4)	Form: Dir	Form: Direct (D) (I or Indirect (I)		4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 4)			2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securit Derivative Security (Instr. 4)	ties Underlyin	Conv	ersion ercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
			Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Deriv Secu	ative	Direct (D) or Indirect (I) (Instr. 5)		
Series A-1 Cor	A-1 Convertible Preferred Stock		(1)	(1)	Common Stock	1,544,397	0.0	00(1)	D		
Convertible Pr	Convertible Promissory Notes		(3)	(3)	Common Stock	\$181,818.1	В	(3)	D		
Series A-1 Preferred Warrants		10/15/2013	10/15/2018	Series A-1 Preferred Stock	532,818 ⁽⁴	0.4	49 ⁽⁴⁾	D			

Explanation of Responses:

- 1. The shares of Series A-1 Preferred Stock have no expiration date and are convertible at any time at the election of the holder. Each share of Series A-1 Preferred Stock will automatically convert on a one-for-one basis into shares of common stock upon the closing of the Issuer's initial public offering.
- 2. Share numbers assume or give effect to the 1-for-12.49 reverse stock split of the Issuer's Common Stock effected on October 25, 2013, which will be effective for the Preferred Stock upon its conversion to Common Stock immediately prior to the closing of the Issuer's initial public offering.
- 3. Consists of principal, that together with accrued interest, will convert immediately prior to the closing of the Issuer's initial public offering into shares of Common Stock at a conversion price equal to the public offering price of the Common Stock sold in the Issuer's initial public offering.
- 4. Share numbers and exercise price do not give effect to the 1-for-12.49 reverse stock split of the Issuer's Common Stock effected on October 25, 2013, which will be effective for the Preferred Stock upon its conversion to Common Stock immediately prior to the closing of the Issuer's initial public offering

Remarks:

/s/ Susan Grant, Assistant

Secretary on behalf of Pfizer

01/29/2014

Inc.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.